Alpha-adrenoceptor-mediated actions of optical isomers and desoxy analogs of catecholimidazoline and norepinephrine in human platelets

In vitro

Ahn Chang-Ho, Akihiko Hamada, Duane Miller, Dennis R. Feller

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Adrenoceptor-mediated effects of the enantiomers of optically active imidazoline, 2-(3,4,α-trihydroxybenzyl imidazoline (catecholimidazoline; CI), and norepinephrine (NE), and the corresponding desoxy derivatives, 2-(3,4-dihydroxybenzyl)imidazoline (desoxy-CI) and dopamine, have been investigated in human platelets. Differences between responsiveness of platelets from donor to donor were observed in the presence of the isomers and the desoxy analogs of NE and CI. In certain platelet preparations, all compounds gave concentration-dependent stimulatory responses, whereas in other preparations, only R(-)-NE and R(-)-CI were inducers of platelet aggregation and serotonin release. The rank order of stimulatory potencies (ec50; μM) for CI and NE was R(-)-NE (1.3) > R(-)-CI (7.5) > S(+)-NE (19) = S (+)-CI (20) = dopamine (22) > desoxy-CI (>35). Unlike R(-)-CI, both S(+)-CI and desoxy-CI were either agonists or antagonists of human platelet function. In preparations unresponsive to the S(+)-isomers or desoxy analogs, the potencies (EC50) for R(-)-NE and R(-)-CI were 1.7 and 7.7 μM respectively. The corresponding inactive CIs [S(+)-CI and desoxy-CI] were inhibitors of both primary and secondary phases of aggregation and serotonin release responses to R(-)-CI and R(-)-NE, respectively. In contrast, the aggregation responses to ADP, arachidonic acid or U46619 were not blocked by S(+)-CI or desoxy CI. The rank order of inhibitory potencies for selected α-adrenoceptor agents against R(-)-NE was phentolamine > clonidine > desoxy-CI > S(+)-CI. Moreover, the relative inhibitory potencies of phentolamine and desoxy-CI against aggregation responses to R(-)-NE and R(-)-CI, respectively, were the same. These results suggest that (1) the enantiomers and desoxy derivatives of CI and NE mediate their effects in human platelets by an interaction with α-adrenoceptors; (2) catecholamines and imidazolines interact with the same α-adrenoceptors in human platelets; (3) the stereochemical requirements of both chemical classes for stimulatory activity in human platelets adhere to the Easson-Stedman hypothesis in this α2-adrenoceptor system; and (4) desoxy-CI possessed the highest potency as an antagonist of α-adrenoceptors which suggests that the hydroxy group at the benzylic carbon atom of these imidazolines may not be required for maximal binding to adrenoceptors in platelets.

Original languageEnglish (US)
Pages (from-to)4095-4102
Number of pages8
JournalBiochemical Pharmacology
Volume35
Issue number22
DOIs
StatePublished - Nov 15 1986
Externally publishedYes

Fingerprint

Platelets
Isomers
Adrenergic Receptors
Norepinephrine
Blood Platelets
Imidazolines
Agglomeration
Enantiomers
Phentolamine
Dopamine
Serotonin
In Vitro Techniques
Derivatives
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Platelet Aggregation Inhibitors
Clonidine
Platelet Aggregation
Arachidonic Acid
Human Activities
Adenosine Diphosphate

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

Cite this

Alpha-adrenoceptor-mediated actions of optical isomers and desoxy analogs of catecholimidazoline and norepinephrine in human platelets : In vitro. / Chang-Ho, Ahn; Hamada, Akihiko; Miller, Duane; Feller, Dennis R.

In: Biochemical Pharmacology, Vol. 35, No. 22, 15.11.1986, p. 4095-4102.

Research output: Contribution to journalArticle

@article{f8da276f037946228b60fec18e92993d,
title = "Alpha-adrenoceptor-mediated actions of optical isomers and desoxy analogs of catecholimidazoline and norepinephrine in human platelets: In vitro",
abstract = "Adrenoceptor-mediated effects of the enantiomers of optically active imidazoline, 2-(3,4,α-trihydroxybenzyl imidazoline (catecholimidazoline; CI), and norepinephrine (NE), and the corresponding desoxy derivatives, 2-(3,4-dihydroxybenzyl)imidazoline (desoxy-CI) and dopamine, have been investigated in human platelets. Differences between responsiveness of platelets from donor to donor were observed in the presence of the isomers and the desoxy analogs of NE and CI. In certain platelet preparations, all compounds gave concentration-dependent stimulatory responses, whereas in other preparations, only R(-)-NE and R(-)-CI were inducers of platelet aggregation and serotonin release. The rank order of stimulatory potencies (ec50; μM) for CI and NE was R(-)-NE (1.3) > R(-)-CI (7.5) > S(+)-NE (19) = S (+)-CI (20) = dopamine (22) > desoxy-CI (>35). Unlike R(-)-CI, both S(+)-CI and desoxy-CI were either agonists or antagonists of human platelet function. In preparations unresponsive to the S(+)-isomers or desoxy analogs, the potencies (EC50) for R(-)-NE and R(-)-CI were 1.7 and 7.7 μM respectively. The corresponding inactive CIs [S(+)-CI and desoxy-CI] were inhibitors of both primary and secondary phases of aggregation and serotonin release responses to R(-)-CI and R(-)-NE, respectively. In contrast, the aggregation responses to ADP, arachidonic acid or U46619 were not blocked by S(+)-CI or desoxy CI. The rank order of inhibitory potencies for selected α-adrenoceptor agents against R(-)-NE was phentolamine > clonidine > desoxy-CI > S(+)-CI. Moreover, the relative inhibitory potencies of phentolamine and desoxy-CI against aggregation responses to R(-)-NE and R(-)-CI, respectively, were the same. These results suggest that (1) the enantiomers and desoxy derivatives of CI and NE mediate their effects in human platelets by an interaction with α-adrenoceptors; (2) catecholamines and imidazolines interact with the same α-adrenoceptors in human platelets; (3) the stereochemical requirements of both chemical classes for stimulatory activity in human platelets adhere to the Easson-Stedman hypothesis in this α2-adrenoceptor system; and (4) desoxy-CI possessed the highest potency as an antagonist of α-adrenoceptors which suggests that the hydroxy group at the benzylic carbon atom of these imidazolines may not be required for maximal binding to adrenoceptors in platelets.",
author = "Ahn Chang-Ho and Akihiko Hamada and Duane Miller and Feller, {Dennis R.}",
year = "1986",
month = "11",
day = "15",
doi = "10.1016/0006-2952(86)90034-1",
language = "English (US)",
volume = "35",
pages = "4095--4102",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "22",

}

TY - JOUR

T1 - Alpha-adrenoceptor-mediated actions of optical isomers and desoxy analogs of catecholimidazoline and norepinephrine in human platelets

T2 - In vitro

AU - Chang-Ho, Ahn

AU - Hamada, Akihiko

AU - Miller, Duane

AU - Feller, Dennis R.

PY - 1986/11/15

Y1 - 1986/11/15

N2 - Adrenoceptor-mediated effects of the enantiomers of optically active imidazoline, 2-(3,4,α-trihydroxybenzyl imidazoline (catecholimidazoline; CI), and norepinephrine (NE), and the corresponding desoxy derivatives, 2-(3,4-dihydroxybenzyl)imidazoline (desoxy-CI) and dopamine, have been investigated in human platelets. Differences between responsiveness of platelets from donor to donor were observed in the presence of the isomers and the desoxy analogs of NE and CI. In certain platelet preparations, all compounds gave concentration-dependent stimulatory responses, whereas in other preparations, only R(-)-NE and R(-)-CI were inducers of platelet aggregation and serotonin release. The rank order of stimulatory potencies (ec50; μM) for CI and NE was R(-)-NE (1.3) > R(-)-CI (7.5) > S(+)-NE (19) = S (+)-CI (20) = dopamine (22) > desoxy-CI (>35). Unlike R(-)-CI, both S(+)-CI and desoxy-CI were either agonists or antagonists of human platelet function. In preparations unresponsive to the S(+)-isomers or desoxy analogs, the potencies (EC50) for R(-)-NE and R(-)-CI were 1.7 and 7.7 μM respectively. The corresponding inactive CIs [S(+)-CI and desoxy-CI] were inhibitors of both primary and secondary phases of aggregation and serotonin release responses to R(-)-CI and R(-)-NE, respectively. In contrast, the aggregation responses to ADP, arachidonic acid or U46619 were not blocked by S(+)-CI or desoxy CI. The rank order of inhibitory potencies for selected α-adrenoceptor agents against R(-)-NE was phentolamine > clonidine > desoxy-CI > S(+)-CI. Moreover, the relative inhibitory potencies of phentolamine and desoxy-CI against aggregation responses to R(-)-NE and R(-)-CI, respectively, were the same. These results suggest that (1) the enantiomers and desoxy derivatives of CI and NE mediate their effects in human platelets by an interaction with α-adrenoceptors; (2) catecholamines and imidazolines interact with the same α-adrenoceptors in human platelets; (3) the stereochemical requirements of both chemical classes for stimulatory activity in human platelets adhere to the Easson-Stedman hypothesis in this α2-adrenoceptor system; and (4) desoxy-CI possessed the highest potency as an antagonist of α-adrenoceptors which suggests that the hydroxy group at the benzylic carbon atom of these imidazolines may not be required for maximal binding to adrenoceptors in platelets.

AB - Adrenoceptor-mediated effects of the enantiomers of optically active imidazoline, 2-(3,4,α-trihydroxybenzyl imidazoline (catecholimidazoline; CI), and norepinephrine (NE), and the corresponding desoxy derivatives, 2-(3,4-dihydroxybenzyl)imidazoline (desoxy-CI) and dopamine, have been investigated in human platelets. Differences between responsiveness of platelets from donor to donor were observed in the presence of the isomers and the desoxy analogs of NE and CI. In certain platelet preparations, all compounds gave concentration-dependent stimulatory responses, whereas in other preparations, only R(-)-NE and R(-)-CI were inducers of platelet aggregation and serotonin release. The rank order of stimulatory potencies (ec50; μM) for CI and NE was R(-)-NE (1.3) > R(-)-CI (7.5) > S(+)-NE (19) = S (+)-CI (20) = dopamine (22) > desoxy-CI (>35). Unlike R(-)-CI, both S(+)-CI and desoxy-CI were either agonists or antagonists of human platelet function. In preparations unresponsive to the S(+)-isomers or desoxy analogs, the potencies (EC50) for R(-)-NE and R(-)-CI were 1.7 and 7.7 μM respectively. The corresponding inactive CIs [S(+)-CI and desoxy-CI] were inhibitors of both primary and secondary phases of aggregation and serotonin release responses to R(-)-CI and R(-)-NE, respectively. In contrast, the aggregation responses to ADP, arachidonic acid or U46619 were not blocked by S(+)-CI or desoxy CI. The rank order of inhibitory potencies for selected α-adrenoceptor agents against R(-)-NE was phentolamine > clonidine > desoxy-CI > S(+)-CI. Moreover, the relative inhibitory potencies of phentolamine and desoxy-CI against aggregation responses to R(-)-NE and R(-)-CI, respectively, were the same. These results suggest that (1) the enantiomers and desoxy derivatives of CI and NE mediate their effects in human platelets by an interaction with α-adrenoceptors; (2) catecholamines and imidazolines interact with the same α-adrenoceptors in human platelets; (3) the stereochemical requirements of both chemical classes for stimulatory activity in human platelets adhere to the Easson-Stedman hypothesis in this α2-adrenoceptor system; and (4) desoxy-CI possessed the highest potency as an antagonist of α-adrenoceptors which suggests that the hydroxy group at the benzylic carbon atom of these imidazolines may not be required for maximal binding to adrenoceptors in platelets.

UR - http://www.scopus.com/inward/record.url?scp=0023029171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023029171&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(86)90034-1

DO - 10.1016/0006-2952(86)90034-1

M3 - Article

VL - 35

SP - 4095

EP - 4102

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 22

ER -